Reported resultsCompany-reported
What was reported
CAMBRIDGE, Mass., May 11, 2026 – Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the first quarter ended March 31, 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 11, 2026 · Open the source ↗
What the evidence supports
Intellia Therapeutics published its results for the period in a press release furnished to the SEC (Form 8-K, Item 2.02).
What remains unknown
Audit status of the figures (results furnished on Form 8-K or 6-K are typically unaudited), and anything about future periods. Any outlook is the company's own projection. Figures and claims are the company's own description and have not been independently verified.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineIntellia Therapeutics Announces First Quarter 2026 Financial Results and Business UpdatesU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 11, 2026 · Open the source ↗
Press release lead paragraphCAMBRIDGE, Mass., May 11, 2026 – Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the first quarter ended March 31, 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 11, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:51 UTC
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.